Home
Novaliq

Novaliq Market Share Analysis for August 2026

novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on eyesol®, the first and only water-free technology worldwide for ophthalmology products.

Industry: N/A

Domainnovaliq.com

Year Founded2004

Employees51 - 200

Annual Revenue$10M - $15M

Novaliq

Novaliq (including company regionals)

novaliq.com

See more website traffic and engagement information

Novaliq Revenue up to August 2026 is 10M - 15M

revenue generated by Novaliq top domains

Novaliq top domains revenue over 3 years

Revenue for Novaliq top domains

novaliq.com10M - 15M

See more with Sales Intelligence

Total visits to Novaliq's top domains

Understand Novaliq market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

novaliq.com5.6K

See more with Sales Intelligence

Avg. visit duration in Novaliq's top domains

Analyze Novaliq engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

novaliq.com00:00:10

See more with Sales Intelligence

Avg. pageviews on Novaliq's top domains

See how Novaliq keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

novaliq.com1.62

See more with Sales Intelligence

Novaliq top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Novaliq

These are the website technologies, by industry, used by Novaliq top domains

Widget (7)

reCAPTCHA

Conversion & Analytics (3)

Google Analytics

Mobile (3)

Meta Viewport

Content Management System (2)

WordPress

More Technologies

8

See all

News & Signals from Novaliq

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHengrui partnered with Novaliq GmbH on Jul 1st '19.Hengrui Pharma, a globally active pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH ("Novaliq"), a biopharmaceutical company focused on first-in-class and best-in-class ophthalmic therapies based on its unique water-free EyeSol platform technology, today announced that on June 23, 2026, the Chinese National Medical Products Administration (NMPA) approved Heng Yi (0.1% cyclosporine eye drops) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and alleviate disease symptoms.

NewsSonja Kroesser at Novaliq GmbH recognized as Top 25 Women Leaders in Biotechnology of 2022 on Nov 17th '22.Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol ® water-free technology, is proud to announce that today its own Sonja Kroesser, Vice President and Head of Preclinical and Clinical Development, was named as a Top 25 Women Leaders in Biotechnology of 2022 by the Healthcare Technology Report.

NewsSonja Kroesser at Novaliq GmbH recognized as Top 25 Women Leaders in Biotechnology of 2022 on Jan 17th '19.Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol ® water-free technology, is proud to announce that today its own Sonja Kroesser, Vice President and Head of Preclinical and Clinical Development, was named as a Top 25 Women Leaders in Biotechnology of 2022 by the Healthcare Technology Report.